Latest News

3D Helical Stent Twelve Month Data Released

Paris, France, 21 May 2013. 3D Helical Stent Twelve Month Data Suggest Correlation between Stented Vessel Curvature and Primary Patency. Data presented during the Trials and Innovations for Peripheral Interventions Session at EuroPCR 2013 show that a stent with unique three-dimensional helical geometry, BioMimics 3D™, developed by Veryan Medical Ltd. - a...


Opsona Therapeutics Ltd. initiates a Phase II Study with OPN-305.

May 7th, 2013, Dublin, Ireland – Seroba Kernel's investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases, today announced that it has initiated a phase II clinical trial in renal transplant patients at high risk of delayed graft function with its...


Opsona Therapeutics Limited raises €33 million Series C equity financing to advance clinical development of its lead product OPN-305.

April 29th, 2013, Dublin, Ireland – Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $43 million) in a Series C financing. The participants in this Series C financing include existing investors, Novartis Venture Fund, Fountain Healthcare Partners, Roche Venture Fund and Seroba-Kernel Life Sciences. The...


< back to home page